Skip to main content
NewslettersWatchlist

Theratechnologies(TH-T)
TSX

Today's Change
Real-Time Last Update
Day Low1.67
Day High1.73
Open:1.73
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
AI-generated - The Globe and Mail
Theratechnologies: Top 10 Undervalued Biotechnology Industry Stocks (TH)
GlobeNewswire
Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV
GlobeNewswire
Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance
GlobeNewswire
Theratechnologies Reports Strong Financial Results and Announces Positive Net Income for Third Quarter 2024
GlobeNewswire
Theratechnologies to Present Data at IDWeek 2024 Highlighting Advances in Treatment and Management of Complications in People with HIV
AI-generated - The Globe and Mail
Theratechnologies: Top 10 Undervalued Biotechnology Industry Stocks (TH)
GlobeNewswire
Theratechnologies to Announce Third Quarter 2024 Financial Results and Provide Business Update
GlobeNewswire
Theratechnologies Announces a Risk of a Temporary Supply Disruption for EGRIFTA SV® in Early 2025
Baystreet
Stocks in play: Theratechnologies Inc.
GlobeNewswire
Theratechnologies to Present at Upcoming Investor Conferences in September
AI-generated - The Globe and Mail
Theratechnologies: Top 10 Undervalued Biotechnology Industry Stocks (TH)
GlobeNewswire
Theratechnologies Reports Financial Results and Announces Positive Net Income for Second Quarter 2024
AI-generated - The Globe and Mail
Theratechnologies: Top 10 Undervalued Biotechnology Industry Stocks (TH)
GlobeNewswire
Theratechnologies to Announce Second Quarter 2024 Financial Results and Provide Business Update
AI-generated - The Globe and Mail
Theratechnologies: Top 10 Undervalued Biotechnology Industry Stocks (TH)
GlobeNewswire
Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
GlobeNewswire
Theratechnologies Reports on its Annual Meeting of Shareholders
GlobeNewswire
Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting
GlobeNewswire
Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders
AI-generated - The Globe and Mail
Theratechnologies: Top 10 Undervalued Biotechnology Industry Stocks (TH)
GlobeNewswire
Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
GlobeNewswire
Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024

Profile

Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.